Insight Acquires Monistat In Third Deal With McNeil For Women’s OTC Drugs
This article was originally published in The Tan Sheet
Executive Summary
Insight Pharmaceutical expanded its women’s health care footprint with the acquisition of the Monistat North American portfolio from McNeil Consumer Healthcare.
You may also be interested in...
J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst
Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.
J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst
Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.
In Brief: Prestige Buys Insight, Quarterly Earnings For MJN And Colgate, Bio-Recovery Warned On Claims
Prestige acquires Insight Pharmaceuticals; Product relaunches boost Novartis’ consumer sales; Colgate’s N.A. sales inch up; Mead Johnson sales up 7%; and Bio-Recovery makes drug claims.